Review of antimicrobial peptides with anti-Helicobacter pylori activity.


Journal

Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 09 2018
revised: 09 10 2018
accepted: 10 10 2018
pubmed: 16 11 2018
medline: 25 4 2019
entrez: 16 11 2018
Statut: ppublish

Résumé

The emergence of antibiotic-resistant Helicobacter pylori strains in recent years has increased the need for finding an alternative in the post-antibiotic era. One of the fields being considered for this purpose is antimicrobial peptides. The aim of this review was to provide an obvious scheme from the studied anti-H. pylori peptides and to investigate their common features. First, all of the antimicrobial peptides with their anti-H. pylori effects have been proved up to September 2018 were selected and their information including structure, mechanism of action, and function was reviewed. To achieve this, three databases of PubMed, Scopus, and Web of science were used. A total of 9 groups containing 22 antimicrobial peptides were found with demonstrated anti-H. pylori effects. The nine groups included pexiganan, tilapia piscidins, epinecidin-1, cathelicidins, defensins, bicarinalin, odorranain-HP, PGLa-AM1, and bacteriocins. Most of the antimicrobial peptides, not all, had common features such as the ability to kill antibiotic-resistant strains, having α-helical structure, being cationic, with high positive charge and isoelectric point. Antimicrobial peptides with anti-H. pylori effects have the potential to replace the antibiotics, especially in the post-antibiotic era, if a rapid and low-cost production method would be found.

Sections du résumé

BACKGROUND BACKGROUND
The emergence of antibiotic-resistant Helicobacter pylori strains in recent years has increased the need for finding an alternative in the post-antibiotic era. One of the fields being considered for this purpose is antimicrobial peptides. The aim of this review was to provide an obvious scheme from the studied anti-H. pylori peptides and to investigate their common features.
METHOD METHODS
First, all of the antimicrobial peptides with their anti-H. pylori effects have been proved up to September 2018 were selected and their information including structure, mechanism of action, and function was reviewed. To achieve this, three databases of PubMed, Scopus, and Web of science were used.
RESULTS RESULTS
A total of 9 groups containing 22 antimicrobial peptides were found with demonstrated anti-H. pylori effects. The nine groups included pexiganan, tilapia piscidins, epinecidin-1, cathelicidins, defensins, bicarinalin, odorranain-HP, PGLa-AM1, and bacteriocins. Most of the antimicrobial peptides, not all, had common features such as the ability to kill antibiotic-resistant strains, having α-helical structure, being cationic, with high positive charge and isoelectric point.
CONCLUSION CONCLUSIONS
Antimicrobial peptides with anti-H. pylori effects have the potential to replace the antibiotics, especially in the post-antibiotic era, if a rapid and low-cost production method would be found.

Identifiants

pubmed: 30440101
doi: 10.1111/hel.12555
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0
Antimicrobial Cationic Peptides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12555

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Alireza Neshani (A)

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

Hosna Zare (H)

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Reza Akbari Eidgahi (MR)

Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran.

Amin Hooshyar Chichaklu (A)

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Aref Movaqar (A)

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Kiarash Ghazvini (K)

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH